I rate Omada Health a buy due to its strong clinical validation, strategic partnerships, and vast untapped market opportunity. OMDA's clinical outcomes, backed by 29 peer-reviewed studies, provide a true moat and credibility with sophisticated buyers like employers and health plans. Strategic partnerships with Cigna and CVS enable rapid scale, lower customer acquisition costs, and improve revenue visibility, accelerating OMDA's growth trajectory.
7 Aug 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
7 Aug 2025 (In 1 week) Date | | - Cons. EPS | - EPS |